Arizil

Arizil Drug Interactions

donepezil

Manufacturer:

Y.S.P. Industries

Distributor:

Y.S.P. Industries
Full Prescribing Info
Drug Interactions
Donepezil hydrochloride and/or any of its metabolites do not inhibit the metabolism of theophylline, warfarin, cimetidine or digoxin in humans.
The metabolism of donepezil hydrochloride is not affected by concurrent administration of digoxin or cimetidine.
Donepezil hydrochloride has the potential to interfere with medications having anticholinergic activity.
There is potential for synergistic activity with concomitant treatment involving medications such as succinylcholine, other neuro-muscular blocking agents or cholinergic agonists or beta blocking agents that have effects on cardiac conduction. Concurrent use of donepezil and succinylcholine may result in prolonged neuromuscular blockade.
No adverse effects related to drug interactions were reported when patients were concomitantly administered donepezil and selective serotonin reuptake inhibitors, neuroleptics or (in a small number of cases) anti-Parkinsonian treatment.
Enzyme inducers, such as rifampicin, phenytoin, carbamazepine and alcohol may reduce the levels of donepezil. Since the magnitude of an inhibiting or inducing effect is unknown, such drug combinations should be used with care.
Concurrent use of donepezil and oxybutynin may result in decreased efficacy of the cholinesterase inhibitor.
Concurrent use of donepezil and tolterodine may result in decreased efficacy of the cholinesterase inhibitor.
Concurrent use of donepezil and ramelteon may result in increased ramelteon exposure.
Concurrent use of donepezil and bethanechol may result in cholinergic adverse effects (bradyarrhythmia, bronchospasm, hyperhidrosis, diarrhea, vomiting).
Concurrent use of donepezil and quinidine may result in increased donepezil bioavailability.
Concurrent use of donepezil and ketoconazole may result in increased donepezil bioavailability.
Other CYP3A4 inhibitors, such as itraconazole and erythromycin, and CYP2D6 inhibitors, such as fluoxetine could inhibit the metabolism of donepezil.
There is also the potential for synergistic activity with concomitant treatment involving beta blocking agents which have effects on cardiac conduction.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in